Latest Conference Articles

April 3rd 2017, 8:45pm

AACR Annual Meeting

According to results presented at the 2017 AACR Annual Meeting, 10% of patients showed impressive long-term survival in a phase I study of single agent anti-PD-L1 atezolizumab (Tecentriq) in patients with metastatic triple-negative breast cancer.

April 3rd 2017, 12:30am

AACR Annual Meeting

Tumor treating fields reduced the risk of death by 37% and overall survival was extended by a median of 5 months for patients with glioblastoma multiforme, in a landmark analysis of the EF-14 trial.

April 2nd 2017, 11:47pm

AACR Annual Meeting

A dual attack on HER2 expression resulted in a 30% objective response rate in heavily pretreated patients with HER2-positive metastatic colorectal cancer.

April 2nd 2017, 9:06pm

AACR Annual Meeting

The irreversible pan-HER tyrosine kinase inhibitor neratinib showed single-agent activity across cohorts of patients with HER2-mutant advanced cancers.

April 2nd 2017, 8:51pm

AACR Annual Meeting

Roger Stupp, MD, professor, Neurological Surgery, and associate director, Strategic Initiatives, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields (TTFields) added to standard chemotherapy in newly diagnosed glioblastoma during the AACR Annual Meeting.

April 2nd 2017, 8:10pm

AACR Annual Meeting

Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.

April 1st 2017, 1:37am

ACCC Annual Meeting, CANCERSCAPE

Jessica Turgon, MBA, of ECG Management Consultants says that changes in 340B Drug Pricing Program rules and the CMS physician payment formula are possible.

April 1st 2017, 1:36am

ACCC Annual Meeting, CANCERSCAPE

Tricia Strusowski, MS, RN, discusses the role of the oncology nurse navigator and how these staffers can help meet outcome and quality standards set by the CMS's OCM.

March 31st 2017, 7:31pm

ACCC Annual Meeting, CANCERSCAPE

The outgoing president of the Association of Community Cancer Centers, Jennie Crews, MD, MMM, FACP reflects on her time as president and the achievements the ACCC made.

March 31st 2017, 3:46am

ACCC Annual Meeting, CANCERSCAPE

While at the annual CANCERSCAPE meeting of ACCC, Kavita Patel, MD, MS, comments on uncertainy in the healthcare environment and key policy to be aware of.

March 31st 2017, 2:30am

ACCC Annual Meeting, CANCERSCAPE

Cary Presant, MD, FACP, FASCO, City of Hope Medical Center, discusses clinical trials and value-based care.

March 30th 2017, 10:49pm

ACCC Annual Meeting, CANCERSCAPE

The Republican-led Affordable Care Act repeal and replace effort has the potential to be revived, but majority leaders may not want to risk further political capital in a battle that could go against them, speakers said at this year's Association of Community Cancer Centers' CANCERSCAPE annual conference.

March 19th 2017, 2:34am

St. Gallen International Breast Cancer Conference

Wolfgang Janni, MD, PhD, University of Ulm, disucusses the management of adverse events in HER2-targeted therapies.

March 19th 2017, 2:30am

St. Gallen International Breast Cancer Conference

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.

March 19th 2017, 12:03am

St. Gallen International Breast Cancer Conference

Neoadjuvant therapy in early breast cancer has evolved during the past 2 decades from use primarily in large inoperable tumors to a standard treatment option for patients with early-stage HER2-positive and triple-negative breast cancer.

March 18th 2017, 10:37pm

St. Gallen International Breast Cancer Conference

Age and the molecular subtype were more closely associated with long-term outcomes compared with the use of either breast-conserving surgery or mastectomy for patients with breast cancer.

March 18th 2017, 9:46pm

St. Gallen International Breast Cancer Conference

Immunotherapy will be most effective as a treatment for breast cancer when it is used to alter the tumor microenvironment, according to a careful examination of studies exploring the immune response presented by Nora Disis, MD.

March 17th 2017, 11:30pm

St. Gallen International Breast Cancer Conference

The paucity of patients participating in clinical trials makes data extrapolation and application complex, calling for a need to explore health technology solutions that tap the potential of real-world data.

March 17th 2017, 10:23pm

St. Gallen International Breast Cancer Conference

Inhibition of CDK4/6 results in improvements in progression-free survival in women with estrogen receptor-positive/HER2-negative metastatic breast cancer whether it is endocrine sensitive or resistant.

March 17th 2017, 8:41pm

State of the Science Summit on GI Malignancies

Andrew Kennedy, MD, speaks on the various approaches used in clinical practice to treat patients who have colorectal cancer with liver metastases.